Ensoma
ensoma.com
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$272.6M
4 rounds on record
Latest round
$53M
Venture round · Sep 2025 · 12 mo ago
Backers
1
F-Prime Capital
The money's age
Due for its next round
12 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 23, 2023
Board appointment Kouki Harasaki, Director · SEC Form D
Jan 9, 2023
New executive Emile Nuwaysir, Executive Officer, Director · SEC Form D
Dec 23, 2022
Raised a round Venture round $129M · SEC Form D
Feb 5, 2021
Raised a round Venture round $40.5M · SEC Form D
2019
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Sep 2025 | $53M | — | Pulse 2.0 |
| Series B | Jun 2023 | $50M | — | Pulse 2.0 |
| Venture round | Dec 2022 | $129M | — | SEC Form D |
| Venture round | Feb 2021 | $40.5M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Ensoma, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Kush ParmarDirectorSEC Form D
Emile NuwaysirExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
F-Prime Capital Investors in similar startupsfunds that back the companies most like this one
backs Mammoth Biosciences
backs Mammoth Biosciences
Similar startupsby what they do, their industry and backers
DeepEn One™ in vivo Microendoscopy Platform. Single-Fibre Endoscope for High-Resolution In Vivo Bioimaging.
Manifold Bio has built the first high-throughput in vivo (HTV) discovery engine—combining massively multiplexed in vivo screening and…
Stylus Medicine, Inc. is a biotechnology company dedicated to developing transformative in vivo genetic medicines.
Developing scalable in-vivo genomic medicine for blood disorders.
Metagenomi is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for…
High science that delivers.. Developing in vivo gene editing therapeutics to transform patient lives.
Overview
The future of medicine lies within us.. Our technology platform enables in vivo engineering of hematopoietic stem cells (HSCs). It combines an off-the-shelf in vivo delivery system with a state-of-the-art gene engineering toolkit.
News
Report
Report
Ensoma Announces First Patient Dosed in Phase 1/2 Clinical Trial of EN-374 for Treatment of X-CGD
Read more
Report
Ensoma: $53 Million Secured To Advance Stem Cell Therapies And Global Clinical Impact
Ensoma, a biotechnology company focused on transforming medicine through one-time, in vivo stem cell therapies, has announced the closing of a $53 million funding round. This investment comes from a group of leading investors who have previously backed th
Read more
Report
Ensoma Inc.
The Nature Index tracks the affiliations of scientific articles from high-quality publications. The research profile for Ensoma Inc. reflects the research output of authors from Ensoma Inc. who published articles in the 145 journals included in the Nature
Read more
Report
Ensoma Announces FDA Clearance of IND Application for First In Vivo HSC-Directed Gene Insertion Therapy
BOSTON, May 12, 2025--Ensoma, a genomic medicines company advancing the future of medicine through one-time, in vivo therapies, today announced U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for its lea
Read more
Report
Ensoma Receives Rare Pediatric Disease and Orphan Drug Designations for EN-374 for Treatment of Chronic Granulomatous Disease
Read more
Report
Ensoma Appoints Accomplished Company Builder and Product Developer, Jim Burns, Ph.D., as Chief Executive Officer
Read more
Report
Ensoma: Genomic Medicines Company Closes $50 Million
Ensoma - a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system - announced the closing of an extension of its Series B financing by $50 million, bringing the total size of the fundi
Read more
Report
In vivo cell therapy technology advances with Ensoma's Twelve Bio acquisition
The concept of in vivo cell therapies moves two steps ahead with the announcements that Ensoma raised $85 million in a series B financing round and ad...
Read more
Report
Show more news
People
Kush Parmar
Director
Emile Nuwaysir
Executive Officer, Director
Paula Soteropoulos
Director
Albert Seymour
Director
Stephen Knight
Director
Mark Chin
Director
Nihal Sinha
Director
Kouki Harasaki
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Boston
United States
HQ